Compare MOLN & GGZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MOLN | GGZ |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 114.0M |
| IPO Year | 2021 | 2013 |
| Metric | MOLN | GGZ |
|---|---|---|
| Price | $3.22 | $15.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $10.22 | N/A |
| AVG Volume (30 Days) | 2.1K | ★ 3.7K |
| Earning Date | 10-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.09 | $13.35 |
| 52 Week High | $5.36 | $17.08 |
| Indicator | MOLN | GGZ |
|---|---|---|
| Relative Strength Index (RSI) | 35.97 | 43.58 |
| Support Level | N/A | $14.71 |
| Resistance Level | $4.21 | $15.47 |
| Average True Range (ATR) | 0.12 | 0.29 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 17.36 | 69.77 |
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.